Ainsworth Alan Patrick, Larsen Michael Hareskov, Ladegaard Lars, Eckardt Jens, Fristrup Claus Wilki, Mortensen Michael Bau
Dan Med J. 2019 Aug;66(8).
Minimally invasive oesophagectomy (MIO) has gained increasing popularity. This study reports the results of the first patients operated using this technique at our department.
All procedures were prospectively registered in a database. Patients were followed until death, two years after surgery or 1 January 2019.
A total of 150 procedures were performed (from 23 November 2015 to 27 February 2018). The median proced-ure time decreased from 350 minutes for the initial 75 pa-tients to 320 minutes for the final 75 patients (p < 0.05). Blood loss decreased from 200 ml to 100 ml (p < 0.05), respectively. The conversion rate for the abdominal procedure was 7% for the initial 75 patients and 8% for the final 75 patients (not significant (NS)). For the thoracic procedure, the corresponding figures were 11% and 7% (NS), respectively. Anastomotic leakage was seen in 17% (initial patients) and 11% (final patients) (NS); however, less than 20% of the leakages needed surgical treatment. The median length of post-operative stay was nine days for both groups. For all 150 patients, pulmonary complications were observed in 18% and cardiac complications in 11%. The 30-day mortality rate was 2% and the one-year survival rate was 86% (124 registered patients).
MIO was introduced at our department with acceptable morbidity and mortality rates and the short-term oncological result was not compromised.
none.
The study was approved as a quality project by the Region of Southern Denmark (18/37355).
微创食管切除术（MIO）越来越受欢迎。本研究报告了在我们科室首例使用该技术进行手术的患者的结果。
所有手术均前瞻性地记录在数据库中。对患者进行随访，直至死亡、术后两年或2019年1月1日。
共进行了150例手术（从2015年11月23日至2018年2月27日）。手术中位时间从最初75例患者的350分钟降至最后75例患者的320分钟（p<0.05）。失血量分别从200毫升降至100毫升（p<0.05）。腹部手术的中转率在最初75例患者中为7%，在最后75例患者中为8%（无统计学意义（NS））。对于胸部手术，相应数字分别为11%和7%（NS）。吻合口漏在最初患者中为17%，在最后患者中为11%（NS）；然而，不到20%的漏需要手术治疗。两组术后住院中位时间均为九天。在所有150例患者中，观察到肺部并发症的发生率为18%，心脏并发症的发生率为11%。30天死亡率为2%，一年生存率为86%（124例登记患者）。
我们科室引入的MIO具有可接受的发病率和死亡率，且短期肿瘤学结果未受影响。
无。
该研究被丹麦南部地区批准为质量项目（18/37355）。
